Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 443

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA

Open access
Goldberg, Sarah B., Narayan, Azeet, Kole, Adam J., Decker, Roy H., Teysir, Jimmitti, Carriero, Nicholas J., Lee, Angela, Nemati, Roxanne, Nath, Sameer K., Mane, Shrikant M., Deng, Yanhong, Sukumar, Nitin, Zelterman, Daniel, Boffa, Daniel J., Politi, Katerina, Gettinger, Scott N., Wilson, Lynn D., Herbst, Roy S., Patel, Abhijit A.·2018·Clinical Cancer Research

Abstract

Purpose: Decisions to continue or suspend therapy with immune checkpoint inhibitors are commonly guided by tumor dynamics seen on serial imaging. However, immunotherapy responses are uniquely challenging to interpret because tumors often shrink slowly or can appear transiently enlarged due to inflammation. We hypothesized that monitoring tumor cell death in real time by quantifying changes in circulating tumor DNA (ctDNA) levels could enable early assessment of immunotherapy efficacy. Experimental Design: We compared longitudinal changes in ctDNA levels with changes in radiographic tumor size and with survival outcomes in 28 patients with metastatic non–small cell lung cancer (NSCLC) receiving immune checkpoint inhibitor therapy. CtDNA was quantified by determining the allele fraction of cancer-associated somatic mutations in plasma using a multigene next-generation sequencing assay. We defined a ctDNA response as a >50% decrease in mutant allele fraction from baseline, with a second confirmatory measurement. Results: Strong agreement was observed between ctDNA response and radiographic response (Cohen's kappa, 0.753). Median time to initial response among patients who achieved responses in both categories was 24.5 days by ctDNA versus 72.5 days by imaging. Time on treatment was significantly longer for ctDNA responders versus nonresponders (median, 205.5 vs. 69 days; P < 0.001). A ctDNA response was associated with superior progression-free survival [hazard ratio (HR), 0.29; 95% CI, 0.09–0.89; P = 0.03], and superior overall survival (HR, 0.17; 95% CI, 0.05–0.62; P = 0.007). Conclusions: A drop in ctDNA level is an early marker of therapeutic efficacy and predicts prolonged survival in patients treated with immune checkpoint inhibitors for NSCLC. Clin Cancer Res; 24(8); 1872–80. ©2018 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-1341

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 443

Metadata

Authors
Goldberg, S. B., Narayan, A., Kole, A. J., Decker, R. H., Teysir, J., Carriero, N. J., Lee, A., Nemati, R., Nath, S. K., Mane, S. M., Deng, Y., Sukumar, N., Zelterman, D., Boffa, D. J., Politi, K., Gettinger, S. N., Wilson, L. D., Herbst, R. S., & Patel, A. A.
Venue
Clinical Cancer Research
Published
2018-04-12
Volume
24
Issue
8
Pages
1872-1880
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2783576981
Cited by
443
References
26
FWCI
14.41
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-1341
The paper
Goldberg, S. B., Narayan, A., Kole, A. J., Decker, R. H., Teysir, J., Carriero, N. J., Lee, A., Nemati, R., Nath, S. K., Mane, S. M., Deng, Y., Sukumar, N., Zelterman, D., Boffa, D. J., Politi, K., Gettinger, S. N., Wilson, L. D., Herbst, R. S., & Patel, A. A. (2018). Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-1341

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.